Prognostic value of the TGFβ1 rs4803455 single nucleotide polymorphism in small cell lung cancer.
Adult
Aged
Antineoplastic Agents
/ therapeutic use
Cranial Irradiation
/ methods
Disease-Free Survival
Female
Genotype
Humans
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Neoplasm Recurrence, Local
/ drug therapy
Polymorphism, Single Nucleotide
/ genetics
Prognosis
Proportional Hazards Models
Prospective Studies
Small Cell Lung Carcinoma
/ drug therapy
Transforming Growth Factor beta1
/ genetics
Small cell lung cancer
TGFβ1
single nucleotide polymorphism
Journal
Tumori
ISSN: 2038-2529
Titre abrégé: Tumori
Pays: United States
ID NLM: 0111356
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
pubmed:
12
8
2020
medline:
22
5
2021
entrez:
12
8
2020
Statut:
ppublish
Résumé
Small cell lung cancer (SCLC) is one of the greatest therapeutic challenges of oncology. Potential associations between single nucleotide polymorphisms in heat shock protein β1 (HSPB1) and transforming growth factor β1 (TGFβ1) and survival have been investigated. A prospective multicenter study of 94 patients with SCLC treated between 2013 and 2016 was conducted. Clinical, tumour-related, therapeutic, and genetic (9 SNPs of The cohort included 77 men and 17 women with a median age of 61 years. Eighty percent presented with limited stage at diagnosis and received thoracic radiation with a median dose of 45 Gy (twice-daily radiation in 42%). Forty-seven percent received concurrent platinum-based chemotherapy and 57% received prophylactic cranial irradiation (PCI). Overall survival (OS) was 34% at 2 years and 16% at 3 years. In multivariate analysis, the rs4803455:CA genotype of the Genetic analysis showed the CA genotype of
Sections du résumé
BACKGROUND
BACKGROUND
Small cell lung cancer (SCLC) is one of the greatest therapeutic challenges of oncology. Potential associations between single nucleotide polymorphisms in heat shock protein β1 (HSPB1) and transforming growth factor β1 (TGFβ1) and survival have been investigated.
METHODS
METHODS
A prospective multicenter study of 94 patients with SCLC treated between 2013 and 2016 was conducted. Clinical, tumour-related, therapeutic, and genetic (9 SNPs of
RESULTS
RESULTS
The cohort included 77 men and 17 women with a median age of 61 years. Eighty percent presented with limited stage at diagnosis and received thoracic radiation with a median dose of 45 Gy (twice-daily radiation in 42%). Forty-seven percent received concurrent platinum-based chemotherapy and 57% received prophylactic cranial irradiation (PCI). Overall survival (OS) was 34% at 2 years and 16% at 3 years. In multivariate analysis, the rs4803455:CA genotype of the
CONCLUSIONS
CONCLUSIONS
Genetic analysis showed the CA genotype of
Identifiants
pubmed: 32779517
doi: 10.1177/0300891620946841
doi:
Substances chimiques
Antineoplastic Agents
0
TGFB1 protein, human
0
Transforming Growth Factor beta1
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM